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Introduction: Erlotinib is useful in advanced non-small cell lung
cancer although compliance and efficacy are diminished by skin rash
in a high proportion of patients, often necessitating dose reduction or
drug withdrawal. No effective treatment for the rash is available.
Methods: We carried out a preliminary investigation on isotretinoin
and clindamycin. Among 56 advanced lung cancer patients treated with
erlotinib, 31 (53%) developed rash. Seven (35%) of the 20 G2/G3 cases
agreed to treatment with clindamycin (450 mg/d, days 1–10; 300 mg/d,
days 11–20) plus isotretinoin (20 mg/d, days 11–20) after being in-
formed of the experimental nature of the combination.
Results: In 6 of 7 (86%) patients, the rash resolved (G1/G0) without dose
reduction; in the other patient (G3), the erlotinib dose also had to be
reduced. Median time to resolution was 14 days (range 7–20 days). No
rash-treatment adverse events occurred during 20 days of administration.
Conclusions: Isotretinoin plus clindamycin promises to be the first
effective treatment for erlotinib rash and is being tested further.
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Erlotinib is a selective inhibitor of the tyrosine kinase partof the epidermal growth factor receptor (EGFR) that has
proved effective as second- or third-line therapy for non-
small cell lung cancers (NSCLCs), 40 to 80% of which
overexpress EGFR.1 The most important erlotinib-related
adverse event is an acne-like papulopustular skin rash mainly
affecting the face, scalp, and upper torso.2 Rash develops in
approximately 60 to 80% of erlotinib-treated patients and is
severe (G3–G4) in 5 to 20% of cases.3
Approximately 12% of patients require erlotinib dose
reduction or complete drug withdrawal because of the rash.1,4
In addition to intermittent or permanent erlotinib suspension
and dose reduction, aspecific therapies are also applied in-
cluding systemic and topical antibiotics, antihistamines, top-
ical corticosteroids, and retinoids.5–7 However, clinical trials
on rash management have not been performed.
The antibiotic clindamycin is a common topical and
systemic treatment for acne. Systemic clindamycin may po-
tentiate polymorphonuclear leukocyte chemotaxis,8 and when
compared with tetracycline, clindamycin causes little resis-
tance to Staphylococcus aureus.9
Retinoids, including isotretinoin, are also commonly used
to treat acne. Isotretinoin has been used successfully to treat skin
lesions induced by the EGFR-blocking agent cetuximab.10,11
Isotretinoin may act by several mechanisms including a normal-
izing effect on epithelium and inflammatory mediators.11
We hypothesized that sequential use of clindamycin
and isotretinoin might be effective in erlotinib-induced skin
rash12 and decided to try out the combination on NSCLC
patients who developed skin rash.
METHODS
We treated 56 advanced NSCLC patients (stage III or
IV, not suitable for surgery) from April 2008 to September
2009 with erlotinib (150 mg/d) after obtaining informed
consent, mainly as second- or third-line therapy. Adverse
events including rash were assessed according to Common
Terminology Criteria for Adverse Events 3.0.13
Patients who developed G2/G3 skin rash were asked
whether they wished to be treated for the rash with the
experimental combination of clindamycin and isotretinoin
after being informed of possible side effects of isotretinoin
(particularly liver damage and photosensitivity).
Consenting patients were started on oral clindamycin (450
mg/d, days 1–10; 300 mg/d, days 11–20) plus oral isotretinoin
(20 mg/d, days 11–20) and were examined clinically with
photographic documentation on days 0, 15, and 30.
RESULTS
The most common side effect was cutaneous rash in 31
of 56 (53%) patients: G1 in 11 (19%), G2 in 12 (20%), and
G3 in 8 (14%). Median time or rash onset was 14 days (range
5–60 days) from the start of erlotinib treatment.
Only 7 of 20 (35%) of the eligible (G2/G3) patients
consented to receive clindamycin plus isotretinoin. The two-
drug combination was effective in six (86%) of the seven
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treated patients, with resolution of rash to G1/G0; in the other
patient (G3), it was necessary to reduce erlotinib to 100 mg/d.
Median time to rash resolution was 14 days (range 7–20 days)
in these seven patients. The Figures 1 and 2 show one patient
before and after 15 days of clindamycin plus isotretinoin
treatment. No adverse events associated with clindamycin or
isotretinoin were observed during the 20 days of treatment.
Of the 41 of 56 patients evaluable for erlotinib response, 9
(22%) had an objective response, whereas disease progres-
sion occurred in 25 (45%). Cutaneous rash (all grades)
seemed related to erlotinib activity: 7 (78%) patients with
response developed rash, whereas 13 (52%) patients with
progressive disease did not develop rash.
DISCUSSION
Also being well tolerated, isotretinoin plus clindamycin
did not seem to adversely affect the clinical activity of
erlotinib. Thus, objective responses occurred in 44% of pa-
tients treated for cutaneous rash against 22% of the evaluable
population; for stable disease and disease progression, the
corresponding percentages were 28 versus 17% and 28 versus
61%, respectively. Although these percentages refer to very
small numbers of patients and require verification, they are
clinically impressive.
These findings and other data14,15 suggest that rash
could be a clinical marker predicting therapy success, further
suggesting that dose reduction or drug withdrawal compro-
mises the effectiveness of erlotinib.
To conclude, the results of this preliminary study indi-
cate that sequential clindamycin and isotretinoin have prom-
ise as an effective means of managing erlotinib-induced skin
rash, allowing maintenance of effective erlotinib dose and
hence maximizing efficacy. A randomized phase II study to
further explore efficacy is planned and will include a neutro-
phil chemotaxis assay on peripheral blood to further investi-
gate the supposed rationale of the combination.
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FIGURE 1. Day 0. Cutaneous rash after 15 days of erlotinib
at 150 mg/d.
FIGURE 2. Day 15. Cutaneous rash after 30 days of erlo-
tinib (150 mg/d) plus 15 days of therapy with clindamycin
and isotretinoin.
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